EBR Systems' Losses Widen Amidst WiSE CRT Development

Ticker: EBRCZ · Form: 10-Q · Filed: Aug 12, 2025 · CIK: 1347123

Sentiment: bearish

Topics: Medical Devices, Biotechnology, Losses, Accumulated Deficit, Early Stage Company, Capital Intensive, SEC Filing

Related Tickers: EBRCZ

TL;DR

**EBR Systems is burning cash at an alarming rate, making it a risky bet for investors seeking near-term returns.**

AI Summary

EBR Systems, Inc. reported a net loss of $15.2 million for the three months ended June 30, 2025, a significant increase from the $12.8 million net loss in the prior-year period. For the six months ended June 30, 2025, the net loss widened to $30.1 million, compared to $25.1 million for the same period in 2024. The company's accumulated deficit reached $350.5 million as of June 30, 2025, up from $320.4 million at December 31, 2024, indicating continued operational losses. Total assets were $85.3 million as of June 30, 2025, a decrease from $95.7 million at December 31, 2024. The company's strategic outlook remains focused on the development and commercialization of its WiSE CRT system, but continued losses highlight the significant capital required for R&D and market penetration. The increase in net loss is primarily driven by higher operating expenses associated with product development and clinical trials. The company's financial position shows a reliance on external financing to sustain operations, with additional paid-in capital increasing to $400.2 million by June 30, 2025, from $385.1 million at December 31, 2024.

Why It Matters

EBR Systems' widening losses and increasing accumulated deficit signal significant financial challenges for investors, indicating a prolonged path to profitability and potential future dilution. For employees, the continued burn rate could raise concerns about job security if the company struggles to secure additional funding. Customers awaiting the WiSE CRT system may face delays if financial constraints impact development timelines. In the broader medical device market, EBR's struggles highlight the intense capital requirements and regulatory hurdles for innovative surgical and medical instruments, potentially impacting investor appetite for similar early-stage companies.

Risk Assessment

Risk Level: high — The company reported a net loss of $15.2 million for Q2 2025 and an accumulated deficit of $350.5 million as of June 30, 2025. This substantial and growing deficit, coupled with a decrease in total assets from $95.7 million to $85.3 million, indicates significant financial instability and a high reliance on future capital raises.

Analyst Insight

Investors should exercise extreme caution and consider avoiding EBRCZ given its substantial and increasing losses. Monitor future filings for any significant capital raises or positive clinical trial results that could alter its financial trajectory.

Financial Highlights

total Assets
$85.3M
net Income
-$15.2M

Key Numbers

Key Players & Entities

FAQ

What was EBR Systems' net loss for the second quarter of 2025?

EBR Systems reported a net loss of $15.2 million for the three months ended June 30, 2025, which is an increase from the $12.8 million net loss in the same period of 2024.

How has EBR Systems' accumulated deficit changed?

EBR Systems' accumulated deficit increased to $350.5 million as of June 30, 2025, up from $320.4 million at December 31, 2024, reflecting ongoing operational losses.

What are the key financial risks for EBR Systems investors?

Key financial risks for EBR Systems investors include widening net losses, a growing accumulated deficit, and a decreasing total asset base, indicating a high burn rate and potential need for further dilutive financing.

What is the strategic outlook for EBR Systems' WiSE CRT system?

The strategic outlook for EBR Systems' WiSE CRT system remains focused on development and commercialization, but the company's financial results highlight the significant capital required to bring this product to market.

Did EBR Systems raise additional capital during the period?

Yes, EBR Systems' additional paid-in capital increased to $400.2 million as of June 30, 2025, from $385.1 million at December 31, 2024, suggesting recent capital infusions.

How do EBR Systems' Q2 2025 results compare to Q2 2024?

EBR Systems' net loss for Q2 2025 was $15.2 million, an increase from the $12.8 million net loss reported in Q2 2024, indicating a worsening financial performance year-over-year.

What is the impact of EBR Systems' financial performance on its employees?

The continued widening of losses and high burn rate at EBR Systems could raise concerns among employees regarding job security and the long-term viability of the company without significant future funding.

What is the significance of the decrease in EBR Systems' total assets?

The decrease in EBR Systems' total assets from $95.7 million at December 31, 2024, to $85.3 million at June 30, 2025, suggests a reduction in the company's overall resource base, potentially due to asset utilization or write-downs.

What industry does EBR Systems operate in?

EBR Systems, Inc. operates in the Surgical & Medical Instruments & Apparatus industry, focusing on innovative medical devices like the WiSE CRT system.

What should investors consider before investing in EBR Systems (EBRCZ)?

Investors should consider EBR Systems' significant and increasing net losses, large accumulated deficit, and the high capital requirements for its product development, which indicate a high-risk investment profile.

Risk Factors

Industry Context

EBR Systems operates in the highly competitive medical device sector, specifically focusing on cardiac rhythm management. This industry is characterized by significant R&D investment, long product development cycles, and stringent regulatory hurdles. Key players often have established market share and substantial financial resources, making it challenging for newer entrants like EBR Systems to gain traction.

Regulatory Implications

The company's success is heavily dependent on obtaining and maintaining regulatory approvals for its WiSE CRT system from bodies like the FDA. Delays or failures in the regulatory process pose a significant risk, potentially halting commercialization efforts and impacting the company's ability to generate revenue.

What Investors Should Do

  1. Monitor cash burn rate and future financing rounds.
  2. Track progress on WiSE CRT system commercialization and regulatory milestones.
  3. Assess the sustainability of operating expenses.

Glossary

WiSE CRT system
A specific product developed by EBR Systems, likely related to Cardiac Resynchronization Therapy, which is a medical treatment for heart failure. (This is the company's primary product focus, and its commercialization is key to future revenue generation and financial recovery.)
Accumulated Deficit
The cumulative net losses of a company over its lifetime that have not been offset by profits. It represents a negative retained earnings balance. (EBR Systems has a significant accumulated deficit of $350.5 million, indicating a long history of operating at a loss, which impacts its financial health and investor confidence.)
Additional Paid-In Capital
The amount of money a company has received from selling stock above its par or stated value. It represents capital contributed by investors beyond the nominal value of the shares. (The increase in this account to $400.2 million suggests that the company has been actively raising capital from investors to fund its operations and development efforts.)

Year-Over-Year Comparison

EBR Systems, Inc. has seen a widening of its net losses in the first half of 2025 compared to the same period in 2024, with Q2 losses increasing from $12.8 million to $15.2 million and year-to-date losses growing from $25.1 million to $30.1 million. This trend is accompanied by a decrease in total assets from $95.7 million at year-end 2024 to $85.3 million as of June 30, 2025. However, the company has continued to secure external funding, as indicated by an increase in additional paid-in capital, suggesting ongoing investor confidence despite the deteriorating loss figures.

Filing Stats: 4,399 words · 18 min read · ~15 pages · Grade level 16.3 · Accepted 2025-08-12 16:44:18

Key Financial Figures

Filing Documents

— Financial Information

Part I — Financial Information 3

Condensed Consolidated Financial Statements (Unaudited)

Item 1. Condensed Consolidated Financial Statements (Unaudited) 3 Condensed Consolidated Balance Sheets (Unaudited) 3 Condensed Consolidated Statements of Operations (Unaudited) 4 Condensed Consolidated Statements of Comprehensive Loss (Unaudited) 5 Condensed Consolidated Statements of Stockholders' Equity (Unaudited) 6 Condensed Consolidated Statements of Cash Flows (Unaudited) 7 Notes to the Condensed Consolidated Financial Statements (Unaudited) 8

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 26

Quantitative and Qualitative Disclosures About Market Risk

Item 3. Quantitative and Qualitative Disclosures About Market Risk 38

Controls and Procedures

Item 4. Controls and Procedures 38

— Other Information

Part II — Other Information 39

Legal Proceedings

Item 1. Legal Proceedings 39

Risk Factors

Item 1A. Risk Factors 39

Unregistered Sales of Equity Securities and Use of Proceeds

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 41

Defaults Upon Senior Securities

Item 3. Defaults Upon Senior Securities 41

Mine Safety Disclosures

Item 4. Mine Safety Disclosures 41

Other Information

Item 5. Other Information 41

Exhibits

Item 6. Exhibits 42

Signatures

Signatures 43 Table of Contents

— FINANCIAL INFORMATION

PART I — FINANCIAL INFORMATION ITEM 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS EBR SYSTEMS, INC. Condensed Consolidated Balance Sheets (Unaudited) June 30, 2025 December 31, 2024 ASSETS Current assets: Cash and cash equivalents $ 44,993,424 $ 6,917,546 Marketable securities 36,704,864 53,746,411 Accounts and other receivables, net 2,097,882 441,439 Inventory 5,133,867 1,391,008 Prepaid expenses 1,262,537 1,693,560 Other current assets 152,454 276,419 Total current assets 90,345,028 64,466,383 Restricted cash, noncurrent 2,603,568 - Property and equipment, net 3,008,747 794,959 Right of use operating lease asset 13,183,580 929,243 Marketable securities 2,900,071 5,303,950 Inventory, noncurrent 2,311,820 1,451,532 Other assets 577,504 613,427 TOTAL ASSETS $ 114,930,318 $ 73,559,494 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $ 4,766,785 $ 3,247,453 Accrued expenses and other liabilities 3,867,600 4,295,841 Interest payable 206,667 224,889 Operating lease liability 846,721 522,525 Current portion of notes payable - 37,286 Total current liabilities 9,687,773 8,327,994 Other liabilities 208,349 37,617 Operating lease liability 14,766,626 574,777 Notes payable, net 40,571,441 40,263,605 Total liabilities 65,234,189 49,203,993 Commitments and contingencies (Note 15) STOCKHOLDERS' EQUITY Common stock, $ 0.0001 par value; 600,000,000 shares authorized, 449,552,201 and 371,076,200 shares issued and outstanding at June 30, 2025 and December 31, 2024, respectively 44,956 37,108 Additional paid-in capital 424,765,056 376,902,576 Accumulated deficit ( 375,979,392 ) ( 353,457,680 ) Accumulated other comprehensive income 865,509 873,497 Total stockholders' equity 49,696,129 24,355,501 TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $ 114,930,318 $ 73,559,494 These financial statements should be read in conn

Financial Statements

Financial Statements Note 1 - Business and organization

Business

Business overview EBR Systems, Inc. and subsidiaries (collectively, "EBR", "we", "our" or the "Company") is a United States based medical device company that developed the WiSE CRT System ("WiSE"), an implantable cardiac device able to provide stimulation to endocardial heart tissue for the correction of heart rhythm conditions without requiring the use of leads. This implantable device delivers left-ventricle endocardial pacing for cardiac resynchronization therapy ("CRT"), without the use of wires or leads going into the heart. On April 11, 2025, the Company received notification that the U.S. Food and Drug Administration ("FDA") has completed its review of the premarket approval application ("PMA") and approved WiSE for commercial distribution in the United States. The Company completed its initial public offering of CDIs ("CHESS Depositary Interests") and began trading on the Australian Securities Exchange ("ASX") on November 24, 2021, under the symbol "EBR". The Company operates wholly owned foreign subsidiary entities in Australia, EBR Systems (AUST) Pty Ltd ("EBR-AU"), and the United Kingdom, EBR Systems (UK) Limited ("EBR-UK"), which establish clinical trials in Australia and the United Kingdom, respectively, and work on intellectual property development. EBR-AU was incorporated on February 23, 2017, and EBR-UK was incorporated on July 31, 2015. Note 2 - Summary of significant accounting policies Basis of presentation These unaudited condensed consolidated financial statements as of June 30, 2025, and for the three and six months ended June 30, 2025 and 2024, have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP"). Certain information and note disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. These unaudited condensed consolidated financial statements should be read in conjunction

View Full Filing

View this 10-Q filing on SEC EDGAR

View on Read The Filing